ClinicalTrials.gg
CompletedNCT05654181Updated Nov 5, 2024Results posted

A First-in-human Study of Single Doses of PF-07328948 Which is Given to Healthy Adult Participants

A Phase 1 interventional study of PF-07328948 and Placebo in Healthy, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-05.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This study is the first clinical study with PF-07328948. The safety, tolerability, and plasma pharmacokinetics and pharmacodynamics of PF-07328948 after administration of escalating, single, oral doses will be evaluated.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female participants of non- and males must be 18 to 60 years of age, inclusive, at the time of signing the Document (ICD).
  2. Female participants of non-childbearing potential and males who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.
  3. Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).

    • Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy).
    • History of infection, , or ; positive testing for HIV, HBsAg, HBcAb, or HCVAb. Hepatitis B vaccination is allowed.
  2. Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality or other conditions or situations related to COVID-19 pandemic that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  3. Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study intervention.
  4. Receipt of a COVID-19 vaccine within 7 days before screening or within 7 days before any visit in which a safety lab is planned. Vaccination with a COVID 19 vaccine that occurs greater than 7 days from either screening or any visit in which a safety lab is planned is permitted.
  5. Previous administration with an product (drug or vaccine) within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer).
  6. Screening supine BP ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), following at least 5 minutes of supine rest.
  7. Renal impairment as defined by an \<75 mL/min/1.73m2 calculated using CKD EPI SCr formulas.
  8. Standard 12-lead that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results (eg, >450 ms, complete LBBB, signs of an acute or indeterminate age myocardial infarction, STT interval changes suggestive of myocardial ischemia, second- or third-degree AV block, or serious bradyarrhythmias or tachyarrhythmias). If the uncorrected QT interval is >450 ms, this interval should be rate corrected using the Fridericia method only and the resulting QTcF should be used for decision-making and reporting.
  9. Participants with ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study specific laboratory and confirmed by a single repeat test, if deemed necessary:

    • or ALT level ≥1.25× ;
    • Total level ≥1.5 × ULN; participants with a history of Gilbert's syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is ≤ULN.
  10. History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening. Binge drinking is defined as a pattern of 5 (male) and 4 (female) or more alcoholic drinks in about 2 hours. As a general rule, alcohol intake should not exceed 14 units per week (1 unit = 8 ounces (240 mL) beer, 1 ounce (30 mL) of 40% spirit, or 3 ounces (90 mL) of wine).
  11. Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Participants will receive up to 4 dose levels of PF-07328948 single dose and up to 2 single doses of matching placebo. Doses will be administered as oral suspensions and each dose level is to be determined.

    Drug: PF-07328948 · Drug: Placebo

  • Experimental
    Cohort 2

    Participants will receive up to 4 dose levels of PF-07328948 single dose and up to 2 single doses of matching placebo. Doses will be administered as oral suspensions and each dose level is to be determined.

    Drug: PF-07328948 · Drug: Placebo

  • Experimental
    Cohort 3

    Participants will receive up to 4 dose levels of PF-07328948 single dose and up to 2 single doses of matching placebo. Doses will be administered as oral suspensions and each dose level is to be determined.

    Drug: PF-07328948 · Drug: Placebo

Interventions

  • investigational drug administered orally

  • DrugPlacebo

    Placebo matching active drug administered orally

06

What researchers measure

Primary outcomes

  1. Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An adverse event is considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were flagged as TEAEs. The algorithm did not consider any events that started prior to the first dose date. Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

    Time frame: Day 1-8 per period, along with the 28-35 day post-final dose follow-up

  2. Number of Participants With Clinical Laboratory Abnormalities Meeting Pre-Defined Categorical Criteria Without Regard to Baseline Abnormality

    Pre-defined categorical criteria for laboratory abnormalities included: lymphocytes/Leukocytes \<0.8 x lower limit of normal (LLN) or \>1.2 x upper limit of normal (ULN); Neutrophils \<0.8 x LLN; Neutrophils/Leukocytes \<0.8 x LLN; Eosinophils/Leukocytes \>1.2 x ULN; Monocytes/Leukocytes \>1.2 x ULN; Bilirubin \>1.5 x ULN; Indirect Bilirubin \>1.5 x ULN; Ketones (Scalar) ≥1; URINE Hemoglobin (Scalar) ≥1; URINE Bilirubin (Scalar) ≥1; Leukocyte Esterase (Scalar) ≥1; and Bacteria (/HPF) \>20.

    Time frame: Day 1-8 per period, along with the 28-35 day post-final dose follow-up

  3. Number of Participants With Vital Signs Abnormalities Meeting Pre-Defined Categorical Criteria

    Vital signs categorical criteria: 1) supine systolic blood pressure (SBP) \<90 millimeters of mercury (mmHg); 2) supine diastolic blood pressure (DBP) \<50 mmHg; 3) supine pulse rate \<40 or \>120 beats per minute (bpm); 4) change from baseline (increase or decrease) in supine SBP greater than or equal to (≥) 30 mmHg; 5) change from baseline (increase or decrease) in supine DBP ≥ 20 mmHg.

    Time frame: Day 1-8 per period, along with the 28-35 day post-final dose follow-up

  4. Number of Participants With Abnormal Electrocardiogram (ECG) Meeting Pre-Defined Categorical Criteria

    ECG categorical criteria: 1. PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): a) ≥300 millisecond (msec), b) ≥25% increase when baseline is \> 200 msec or ≥50% increase when baseline is less than or equal to (≤) 200 msec. 2. QRS interval (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): a) ≥140 msec, b) ≥50% increase from baseline. 3. QTcF interval (QT corrected using the Fridericia formula): a) \>450 msec and ≤480 msec, b) \>480 msec and ≤500 msec, c) \>500 msec, d) \>30 msec and ≤60 msec increase from baseline, e) \>60 msec increase from baseline

    Time frame: Day 1-8 per period, along with the 28-35 day post-final dose follow-up

  5. Change From Baseline in Electrocardiogram (ECG) Parameters (ECG Mean Heart Rate)

    Maximum increase from baseline in ECG Mean Heart Rate was reported.

    Time frame: Day 1-8 per period, along with the 28-35 day post-final dose follow-up

  6. Change From Baseline in ECG Parameters (PR Interval, QRS Duration, and QTcF Interval)

    Maximum increase from baseline in PR Interval, QRS Duration, and QTcF Interval was reported.

    Time frame: Day 1-8 per period, along with the 28-35 day post-final dose follow-up

Secondary outcomes

  1. Maximum Concentration Observed in Plasma (Cmax)

    Maximum observed plasma PF-07328948 concentration. Observed directly from data.

    Time frame: Pre-dose (0 hours) and 0.5 hours, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing of each Period (Periods 1-4)

  2. Time to Achieve Cmax (Tmax)

    Observed directly from data as time of first occurrence.

    Time frame: Pre-dose (0 hours) and 0.5 hours, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing of each Period (Periods 1-4)

  3. Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Measured Concentration (AUClast)

    Area under the plasma concentration time-curve from zero to the last measured concentration. It was determined by using linear/Log trapezoidal method.

    Time frame: Pre-dose (0 hours) and 0.5 hours, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing of each Period (Periods 1-4)

  4. Area Under the Plasma Concentration-Time Curve From Time Zero to Extrapolated Infinite Time (AUCinf)

    Area under the plasma concentration-time curve from time 0 extrapolated to infinite time. AUCinf = AUClast + (Clast\*/kel), where Clast\* is the predicted plasma concentration at the last quantifiable timepoint estimated from the log-linear regression analysis, and Kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve, AUClast = Area under the plasma concentration time-curve from zero to the last measured concentration.

    Time frame: Pre-dose (0 hours) and 0.5 hours, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing of each Period (Periods 1-4)

  5. Terminal Half-Life (t1/2) of PF-07328948

    Terminal elimination half-life. t1/2 = Loge(2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. Only those data points judged to describe the terminal log linear decline will be used in the regression.

    Time frame: Pre-dose (0 hours) and 0.5 hours, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing of each Period (Periods 1-4)

07

Results

Posted Nov 5, 2024

Participant flow

Participant flow — Overall Study
MilestonePF-07328948 10 mg, PF-07328948 30 mg, PF-07328948 100 mg, PlaceboPF-07328948 10 mg, PF-07328948 30 mg, Placebo, PF-07328948 300 mgPF-07328948 10 mg, Placebo, PF-07328948 100 mg, PF-07328948 300 mgPlacebo, PF-07328948 30 mg, PF-07328948 100 mg, PF-07328948 300 mgPF-07328948 750 mg, PF-07328948 F mg, PF-07328948 G mg, PlaceboPlacebo, PF-07328948 F mg, PF-07328948 G mg, PF-07328948 H mgPF-07328948 300 mg, PF-07328948 750 mg, PF-07328948 1500 mg, PF-07328948 750 mg (Fed)PF-07328948 300 mg, PF-07328948 750 mg, Placebo, PF-07328948 750 mg (Fed)PF-07328948 300 mg, Placebo, PF-07328948 1500 mg, Placebo (Fed)Placebo, PF-07328948 750 mg, PF-07328948 1500 mg, PF-07328948 750 mg (Fed)
Started3222112322
Completed2222002122
Not completed1000110200
Withdrew: Adverse event1000000100
Withdrew: Withdrawal by subject0000000100
Withdrew: Other0000110000

Outcome measures

PrimaryNumber of Participants Reporting Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An adverse event is considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were flagged as TEAEs. The algorithm did not consider any events that started prior to the first dose date. Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

Time frame:
Day 1-8 per period, along with the 28-35 day post-final dose follow-up
Reported as:
Count of participants · Participants
Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs)
ParticipantsPlaceboPlacebo (Fed)PF-07328948 10 mgPF-07328948 30 mgPF-07328948 100 mgPF-07328948 300 mgPF-07328948 750 mgPF-07328948 750 mg (Fed)PF-07328948 1500 mg
All-causality AEs313215312
Treatment-related AEs100004201
All-causality SAEs100000000
Treatment-related SAEs100000000
PrimaryNumber of Participants With Clinical Laboratory Abnormalities Meeting Pre-Defined Categorical Criteria Without Regard to Baseline Abnormality

Pre-defined categorical criteria for laboratory abnormalities included: lymphocytes/Leukocytes \<0.8 x lower limit of normal (LLN) or \>1.2 x upper limit of normal (ULN); Neutrophils \<0.8 x LLN; Neutrophils/Leukocytes \<0.8 x LLN; Eosinophils/Leukocytes \>1.2 x ULN; Monocytes/Leukocytes \>1.2 x ULN; Bilirubin \>1.5 x ULN; Indirect Bilirubin \>1.5 x ULN; Ketones (Scalar) ≥1; URINE Hemoglobin (Scalar) ≥1; URINE Bilirubin (Scalar) ≥1; Leukocyte Esterase (Scalar) ≥1; and Bacteria (/HPF) \>20.

Time frame:
Day 1-8 per period, along with the 28-35 day post-final dose follow-up
Reported as:
Count of participants · Participants
Number of Participants With Clinical Laboratory Abnormalities Meeting Pre-Defined Categorical Criteria Without Regard to Baseline Abnormality
ParticipantsPlaceboPlacebo (Fed)PF-07328948 10 mgPF-07328948 30 mgPF-07328948 100 mgPF-07328948 300 mgPF-07328948 750 mgPF-07328948 750 mg (Fed)PF-07328948 1500 mg
Number of Participants With Clinical Laboratory Abnormalities Meeting Pre-Defined Categorical Criteria Without Regard to Baseline Abnormality001213312
PrimaryNumber of Participants With Vital Signs Abnormalities Meeting Pre-Defined Categorical Criteria

Vital signs categorical criteria: 1) supine systolic blood pressure (SBP) \<90 millimeters of mercury (mmHg); 2) supine diastolic blood pressure (DBP) \<50 mmHg; 3) supine pulse rate \<40 or \>120 beats per minute (bpm); 4) change from baseline (increase or decrease) in supine SBP greater than or equal to (≥) 30 mmHg; 5) change from baseline (increase or decrease) in supine DBP ≥ 20 mmHg.

Time frame:
Day 1-8 per period, along with the 28-35 day post-final dose follow-up
Reported as:
Count of participants · Participants
Number of Participants With Vital Signs Abnormalities Meeting Pre-Defined Categorical Criteria
ParticipantsPlaceboPlacebo (Fed)PF-07328948 10 mgPF-07328948 30 mgPF-07328948 100 mgPF-07328948 300 mgPF-07328948 750 mgPF-07328948 750 mg (Fed)PF-07328948 1500 mg
SBP <90 mmHg000000100
Change from baseline in SBP ≥30 mmHg decrease000000000
Change from baseline in SBP ≥30 mmHg increase000001000
DBP <50 mmHg000000000
Change from baseline in DBP ≥20 decrease000000000
Change from baseline in DBP ≥20 increase100001000
Pulse rate < 40 bpm000000000
Pulse rate > 120 bpm000001000
PrimaryNumber of Participants With Abnormal Electrocardiogram (ECG) Meeting Pre-Defined Categorical Criteria

ECG categorical criteria: 1. PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): a) ≥300 millisecond (msec), b) ≥25% increase when baseline is \> 200 msec or ≥50% increase when baseline is less than or equal to (≤) 200 msec. 2. QRS interval (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): a) ≥140 msec, b) ≥50% increase from baseline. 3. QTcF interval (QT corrected using the Fridericia formula): a) \>450 msec and ≤480 msec, b) \>480 msec and ≤500 msec, c) \>500 msec, d) \>30 msec and ≤60 msec increase from baseline, e) \>60 msec increase from baseline

Time frame:
Day 1-8 per period, along with the 28-35 day post-final dose follow-up
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Electrocardiogram (ECG) Meeting Pre-Defined Categorical Criteria
ParticipantsPlaceboPlacebo (Fed)PF-07328948 10 mgPF-07328948 30 mgPF-07328948 100 mgPF-07328948 300 mgPF-07328948 750 mgPF-07328948 750 mg (Fed)PF-07328948 1500 mg
PR interval ≥300 msec000000000
%Change in PR interval ≥25/50% increase000000000
QRS interval ≥140 msec000000000
%Change in QRS interval ≥50% increase000000000
QTcF interval >450 and ≤480 msec000000000
QTcF interval >480 and ≤500 msec000000000
QTcF interval >500 msec000000000
Change in QTcF interval >30 and ≤60 msec000000000
Change in QTcF interval >60 msec000000000
PrimaryChange From Baseline in Electrocardiogram (ECG) Parameters (ECG Mean Heart Rate)

Maximum increase from baseline in ECG Mean Heart Rate was reported.

Time frame:
Day 1-8 per period, along with the 28-35 day post-final dose follow-up
Reported as:
Mean · bpm
Change From Baseline in Electrocardiogram (ECG) Parameters (ECG Mean Heart Rate)
bpmPlaceboPlacebo (Fed)PF-07328948 10 mgPF-07328948 30 mgPF-07328948 100 mgPF-07328948 300 mgPF-07328948 750 mgPF-07328948 750 mg (Fed)PF-07328948 1500 mg
Change From Baseline in Electrocardiogram (ECG) Parameters (ECG Mean Heart Rate)9.52 ± 5.17912.45 ± 2.6169.75 ± 2.75212.88 ± 3.3218.36 ± 4.82116.32 ± 14.13215.53 ± 3.89216.32 ± 4.43713.42 ± 3.845
SecondaryMaximum Concentration Observed in Plasma (Cmax)

Maximum observed plasma PF-07328948 concentration. Observed directly from data.

Time frame:
Pre-dose (0 hours) and 0.5 hours, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing of each Period (Periods 1-4)
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Maximum Concentration Observed in Plasma (Cmax)
nanogram per milliliter (ng/mL)PF-07328948 10 mgPF-07328948 30 mgPF-07328948 100 mgPF-07328948 300 mgPF-07328948 750 mgPF-07328948 750 mg (Fed)PF-07328948 1500 mg
Maximum Concentration Observed in Plasma (Cmax)294.7 ± 1111549 ± 117049 ± 1819100 ± 2540220 ± 3337440 ± 1361030 ± 44
SecondaryTime to Achieve Cmax (Tmax)

Observed directly from data as time of first occurrence.

Time frame:
Pre-dose (0 hours) and 0.5 hours, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing of each Period (Periods 1-4)
Reported as:
Median · hours (hr)
Time to Achieve Cmax (Tmax)
hours (hr)PF-07328948 10 mgPF-07328948 30 mgPF-07328948 100 mgPF-07328948 300 mgPF-07328948 750 mgPF-07328948 750 mg (Fed)PF-07328948 1500 mg
Time to Achieve Cmax (Tmax)1.10 (1.00 to 3.00)3.00 (1.00 to 4.00)2.00 (1.50 to 3.00)3.00 (1.50 to 4.00)3.02 (3.00 to 4.02)4.00 (2.00 to 4.03)3.04 (2.00 to 8.03)
SecondaryArea Under the Plasma Concentration-Time Curve From Time Zero to the Last Measured Concentration (AUClast)

Area under the plasma concentration time-curve from zero to the last measured concentration. It was determined by using linear/Log trapezoidal method.

Time frame:
Pre-dose (0 hours) and 0.5 hours, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing of each Period (Periods 1-4)
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*hr/mL)
Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Measured Concentration (AUClast)
nanogram*hour per milliliter (ng*hr/mL)PF-07328948 10 mgPF-07328948 30 mgPF-07328948 100 mgPF-07328948 300 mgPF-07328948 750 mgPF-07328948 750 mg (Fed)PF-07328948 1500 mg
Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Measured Concentration (AUClast)0.0000 ± NA4396 ± 1135030 ± 23110200 ± 30363600 ± 24409300 ± 26742700 ± 24
SecondaryArea Under the Plasma Concentration-Time Curve From Time Zero to Extrapolated Infinite Time (AUCinf)

Area under the plasma concentration-time curve from time 0 extrapolated to infinite time. AUCinf = AUClast + (Clast\*/kel), where Clast\* is the predicted plasma concentration at the last quantifiable timepoint estimated from the log-linear regression analysis, and Kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve, AUClast = Area under the plasma concentration time-curve from zero to the last measured concentration.

Time frame:
Pre-dose (0 hours) and 0.5 hours, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing of each Period (Periods 1-4)
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*hr/mL)
Area Under the Plasma Concentration-Time Curve From Time Zero to Extrapolated Infinite Time (AUCinf)
nanogram*hour per milliliter (ng*hr/mL)PF-07328948 10 mgPF-07328948 30 mgPF-07328948 100 mgPF-07328948 300 mgPF-07328948 750 mgPF-07328948 750 mg (Fed)PF-07328948 1500 mg
Area Under the Plasma Concentration-Time Curve From Time Zero to Extrapolated Infinite Time (AUCinf)——39050 ± 19114300 ± 32378000 ± 26427600 ± 29774600 ± 28
SecondaryTerminal Half-Life (t1/2) of PF-07328948

Terminal elimination half-life. t1/2 = Loge(2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. Only those data points judged to describe the terminal log linear decline will be used in the regression.

Time frame:
Pre-dose (0 hours) and 0.5 hours, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing of each Period (Periods 1-4)
Reported as:
Mean · hours (hr)
Terminal Half-Life (t1/2) of PF-07328948
hours (hr)PF-07328948 10 mgPF-07328948 30 mgPF-07328948 100 mgPF-07328948 300 mgPF-07328948 750 mgPF-07328948 750 mg (Fed)PF-07328948 1500 mg
Terminal Half-Life (t1/2) of PF-07328948——11.58 ± 4.25659.941 ± 2.498016.13 ± 6.527716.90 ± 5.174915.90 ± 5.5106
PrimaryChange From Baseline in ECG Parameters (PR Interval, QRS Duration, and QTcF Interval)

Maximum increase from baseline in PR Interval, QRS Duration, and QTcF Interval was reported.

Time frame:
Day 1-8 per period, along with the 28-35 day post-final dose follow-up
Reported as:
Mean · msec
Change From Baseline in ECG Parameters (PR Interval, QRS Duration, and QTcF Interval)
msecPlaceboPlacebo (Fed)PF-07328948 10 mgPF-07328948 30 mgPF-07328948 100 mgPF-07328948 300 mgPF-07328948 750 mgPF-07328948 750 mg (Fed)PF-07328948 1500 mg
Maximum increase from baseline in PR Interval (msec)5.15 ± 5.5365.10 ± 1.4142.30 ± 4.2602.12 ± 2.1390.80 ± 4.5403.93 ± 3.2156.86 ± 8.70310.00 ± 5.4775.73 ± 1.952
Maximum increase from baseline in QRS Duration (msec)3.54 ± 3.22710.60 ± 3.1111.73 ± 2.5342.44 ± 2.0140.14 ± 0.9694.11 ± 2.8580.91 ± 3.0656.20 ± 3.2514.40 ± 5.303
Maximum increase from baseline in QTcF Interval (msec)6.95 ± 5.9497.40 ± 3.9603.10 ± 4.9003.40 ± 2.8791.78 ± 6.6342.84 ± 4.7026.90 ± 11.8441.50 ± 5.2368.47 ± 8.281

Adverse events

Collected over Day 1-8 per period, along with the 28-35 day post-final dose follow-up. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/13 (0%)1/13 (7.7%)3/13 (23.1%)
Placebo (Fed)0/2 (0%)0/2 (0%)1/2 (50%)
PF-07328948 10 mg0/6 (0%)0/6 (0%)3/6 (50%)
PF-07328948 30 mg0/5 (0%)0/5 (0%)2/5 (40%)
PF-07328948 100 mg0/5 (0%)0/5 (0%)1/5 (20%)
PF-07328948 300 mg0/12 (0%)0/12 (0%)5/12 (41.7%)
PF-07328948 750 mg0/7 (0%)0/7 (0%)3/7 (42.9%)
PF-07328948 750 mg (Fed)0/5 (0%)0/5 (0%)1/5 (20%)
PF-07328948 1500 mg0/6 (0%)0/6 (0%)2/6 (33.3%)
Most frequent serious events
Most frequent serious events
EventPlaceboPlacebo (Fed)PF-07328948 10 mgPF-07328948 30 mgPF-07328948 100 mgPF-07328948 300 mgPF-07328948 750 mgPF-07328948 750 mg (Fed)PF-07328948 1500 mg
SeizureNervous system disorders1/130/20/60/50/50/120/70/50/6
Most frequent other events
Showing 10 of 29
Most frequent other events
EventPlaceboPlacebo (Fed)PF-07328948 10 mgPF-07328948 30 mgPF-07328948 100 mgPF-07328948 300 mgPF-07328948 750 mgPF-07328948 750 mg (Fed)PF-07328948 1500 mg
Dermatitis contactSkin and subcutaneous tissue disorders0/131/20/60/50/50/120/70/50/6
Pharyngitis streptococcalInfections and infestations0/130/20/60/51/50/120/70/50/6
Upper respiratory tract infectionInfections and infestations0/130/20/61/50/50/120/70/50/6
Musculoskeletal chest painMusculoskeletal and connective tissue disorders0/130/20/60/50/50/121/71/50/6
Seasonal allergyImmune system disorders0/130/20/61/50/50/120/70/50/6
Vessel puncture site bruiseGeneral disorders0/130/21/60/50/50/120/70/50/6
COVID-19Infections and infestations0/130/21/60/50/50/120/70/50/6
HeadacheNervous system disorders1/130/21/60/50/52/120/70/50/6
PresyncopeNervous system disorders0/130/20/60/50/50/120/70/51/6
Abdominal painGastrointestinal disorders0/130/20/60/50/50/120/70/51/6

Baseline characteristics

Age, Customized
Age, Customized(Participants)PF-07328948 10 mg, PF-07328948 30 mg, PF-07328948 100 mg, PlaceboPF-07328948 10 mg, PF-07328948 30 mg, Placebo, PF-07328948 300 mgPF-07328948 10 mg, Placebo, PF-07328948 100 mg, PF-07328948 300 mgPlacebo, PF-07328948 30 mg, PF-07328948 100 mg, PF-07328948 300 mgPF-07328948 750 mg, PF-07328948 F mg, PF-07328948 G mg, PlaceboPlacebo, PF-07328948 F mg, PF-07328948 G mg, PF-07328948 H mgPF-07328948 300 mg, PF-07328948 750 mg, PF-07328948 1500 mg, PF-07328948 750 mg (Fed)PF-07328948 300 mg, PF-07328948 750 mg, Placebo, PF-07328948 750 mg (Fed)PF-07328948 300 mg, Placebo, PF-07328948 1500 mg, Placebo (Fed)Placebo, PF-07328948 750 mg, PF-07328948 1500 mg, PF-07328948 750 mg (Fed)Total
18-44 years122211130013
45-60 years20000010227
Sex: Female, Male
Sex: Female, Male(Participants)PF-07328948 10 mg, PF-07328948 30 mg, PF-07328948 100 mg, PlaceboPF-07328948 10 mg, PF-07328948 30 mg, Placebo, PF-07328948 300 mgPF-07328948 10 mg, Placebo, PF-07328948 100 mg, PF-07328948 300 mgPlacebo, PF-07328948 30 mg, PF-07328948 100 mg, PF-07328948 300 mgPF-07328948 750 mg, PF-07328948 F mg, PF-07328948 G mg, PlaceboPlacebo, PF-07328948 F mg, PF-07328948 G mg, PF-07328948 H mgPF-07328948 300 mg, PF-07328948 750 mg, PF-07328948 1500 mg, PF-07328948 750 mg (Fed)PF-07328948 300 mg, PF-07328948 750 mg, Placebo, PF-07328948 750 mg (Fed)PF-07328948 300 mg, Placebo, PF-07328948 1500 mg, Placebo (Fed)Placebo, PF-07328948 750 mg, PF-07328948 1500 mg, PF-07328948 750 mg (Fed)Total
Female10000000023
Male222211232017
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PF-07328948 10 mg, PF-07328948 30 mg, PF-07328948 100 mg, PlaceboPF-07328948 10 mg, PF-07328948 30 mg, Placebo, PF-07328948 300 mgPF-07328948 10 mg, Placebo, PF-07328948 100 mg, PF-07328948 300 mgPlacebo, PF-07328948 30 mg, PF-07328948 100 mg, PF-07328948 300 mgPF-07328948 750 mg, PF-07328948 F mg, PF-07328948 G mg, PlaceboPlacebo, PF-07328948 F mg, PF-07328948 G mg, PF-07328948 H mgPF-07328948 300 mg, PF-07328948 750 mg, PF-07328948 1500 mg, PF-07328948 750 mg (Fed)PF-07328948 300 mg, PF-07328948 750 mg, Placebo, PF-07328948 750 mg (Fed)PF-07328948 300 mg, Placebo, PF-07328948 1500 mg, Placebo (Fed)Placebo, PF-07328948 750 mg, PF-07328948 1500 mg, PF-07328948 750 mg (Fed)Total
Hispanic or Latino01100010104
Not Hispanic or Latino311211131216
Unknown or Not Reported00000000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PF-07328948 10 mg, PF-07328948 30 mg, PF-07328948 100 mg, PlaceboPF-07328948 10 mg, PF-07328948 30 mg, Placebo, PF-07328948 300 mgPF-07328948 10 mg, Placebo, PF-07328948 100 mg, PF-07328948 300 mgPlacebo, PF-07328948 30 mg, PF-07328948 100 mg, PF-07328948 300 mgPF-07328948 750 mg, PF-07328948 F mg, PF-07328948 G mg, PlaceboPlacebo, PF-07328948 F mg, PF-07328948 G mg, PF-07328948 H mgPF-07328948 300 mg, PF-07328948 750 mg, PF-07328948 1500 mg, PF-07328948 750 mg (Fed)PF-07328948 300 mg, PF-07328948 750 mg, Placebo, PF-07328948 750 mg (Fed)PF-07328948 300 mg, Placebo, PF-07328948 1500 mg, Placebo (Fed)Placebo, PF-07328948 750 mg, PF-07328948 1500 mg, PF-07328948 750 mg (Fed)Total
White01200000115
Black or African American01011122019
Asian20010000003
Multiple10000001002
Not reported00000000101
08

Study locations

1 site
  • New Haven Clinical Research Unit
    New Haven, Connecticut 06511, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2022 to primary completion in May 2023, 6 months.

Results were first posted in Nov 2024, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2022
First posted
Dec 16, 2022
StartActual
Oct 17, 2022
Primary completionActual
May 3, 2023
CompletionActual
May 3, 2023
Results first posted
Nov 5, 2024
Last update
Nov 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05654181
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Dec 16, 2022
Start date
Oct 17, 2022
Primary completion
May 3, 2023
Completion
May 3, 2023
Results posted
Nov 5, 2024
Last update
Nov 5, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PF-07328948

Start the discussion